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BaCKgRoUND aND aIMS: Cenicriviroc (CVC) is a 
C-C chemokine receptors type 2 and 5 dual antagonist under 
evaluation for treating liver fibrosis in adults with nonalco-
holic steatohepatitis (NASH). Year 1 primary analysis of the 
2-year CENTAUR study showed that CVC had an antifi-
brotic effect without impacting steatohepatitis. Herein, we re-
port the final data from year 2 exploratory analyses.
appRoaCH aND ReSUltS: This was a randomized, 
controlled study of adults with NASH, nonalcoholic fatty 
liver disease activity score ≥4, and NASH Clinical Research 
Network stage 1-3 fibrosis. Participants in arms A and C re-
ceived CVC 150  mg or placebo, respectively, for 2  years; arm 
B received placebo in year 1 and switched to CVC in year 
2. Liver biopsy was performed at baseline, year 1, and year 
2. Of 289 randomized participants, 242 entered year 2. At 
year 2, 24% of patients who switched to CVC and 17% who 
remained on placebo achieved ≥1-stage fibrosis improvement 
and no worsening of NASH (P  =  0.37). Twice the proportion 
on CVC who achieved fibrosis response at year 1 maintained 
benefit at year 2 (60% arm A versus 30% arm C), includ-
ing 86% on CVC who had stage 3 fibrosis at baseline. Over 
2  years, a similar proportion on CVC or placebo achieved ≥1-
stage fibrosis improvement and no worsening of NASH (15% 
arm A versus 17% arm C). In patients with fibrosis responses, 
we observed consistent reductions in levels of N-terminal type 
3 collagen propeptide and enhanced liver fibrosis scores, while 
increases in aspartate aminotransferase-to-platelet ratio index 
and Fibrosis-4 scores were consistently observed in nonre-
sponders. Safety profile was comparable across groups.
CoNClUSIoNS: CVC was well tolerated, and year 2 data 
corroborate antifibrotic findings from year 1. The major-
ity on CVC who achieved fibrosis response at year 1 main-
tained it at year 2, with greater effect in advanced fibrosis. 
ClinicalTrials.gov number, NCT02217475 (CENTAUR). 
(Hepatology 2020;72:892-905).
Nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease (NAFLD) with an estimated prev-
alence of 1.5%-6.5% in the general population, is 
characterized by inflammation and hepatocyte injury 
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and has an increased risk for liver fibrosis and pro-
gression to cirrhosis.(1,2) Fibrosis severity is the most 
important histological feature of NASH that is an 
independent predictor of long-term clinical outcomes 
and mortality and, if left untreated, can progress to 
cirrhosis and hepatocellular carcinoma, which sub-
sequently increases overall and liver-related mortal-
ity.(3-6) Despite recent advances in understanding the 
mechanisms underlying the pathogenesis of NASH, 
no approved, disease-modifying treatments are cur-
rently available.(7,8)
During hepatic injury, C-C chemokine receptors 
type 2 (CCR2) and 5 (CCR5) and C-C chemokine 
ligands 2 and 5 (CCL2 and CCL5) promote liver 
fibrosis through activation of inflammatory signaling 
and immune cell infiltration.(9-11) Cenicriviroc (CVC) 
is a first-in-class, oral, dual CCR2/CCR5 antagonist 
with potent anti-inflammatory and antifibrotic activ-
ity currently in clinical development for the treatment 
of liver fibrosis associated with NASH.(12) CVC has 
shown a favorable safety profile in over 1,100 trial 
participants, including patients with cirrhosis and 
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mild to severe hepatic impairment, with few reported 
adverse events in studies extending ≥48 weeks.(13-15)
The 2-year phase 2b CENTAUR study was 
designed to examine the efficacy and safety of once-
daily treatment with CVC 150 mg compared to placebo 
in adult participants with NASH and liver fibrosis, for 
which it received fast-track designation by the Food 
and Drug Administration.(15) Data from the year 1 
primary analysis of the 2-year study demonstrated 
that CVC treatment resulted in liver fibrosis improve-
ment without impact on underlying steatohepatitis 
compared to placebo (i.e., ≥1-stage improvement in 
fibrosis and no worsening of NASH; 20% versus 10%; 
odds ratio [OR], 2.2; 95% confidence interval [CI], 
1.11-4.35; P  =  0.02).(16) Moreover, CVC treatment 
was associated with reduced biomarkers of systemic 
inflammation, including C-reactive protein (CRP), 
interleukin (IL)-6, IL-1β, and fibrinogen, supporting 
its antifibrotic and anti-inflammatory mechanism of 




The study design, rationale, and full eligibility cri-
teria have been described.(15) This was a phase 2b, 
randomized, double-blind, placebo-controlled, mul-
ticenter study of CVC for the treatment of adult 
patients with NASH and liver fibrosis. Adults aged 
18-75  years with histological evidence of NASH, a 
NAFLD activity score (NAS) ≥4 with at least 1 in 
each component, and liver fibrosis (NASH Clinical 
Research Network [CRN] stages 1-3) were enrolled 
in 81 sites across the United States, Australia, Hong 
Kong, and Europe.  The protocol and informed con-
sent form (ICF) were approved by the Institutional 
Review Board (IRB) for each center prior to study 
initiation and all participants provided written 
informed consent. All authors had access to the data 
and reviewed and approved the final manuscript.
Eligible participants were randomized 2:1:1 to CVC 
150 mg (arm A) or placebo (arms B and C) once daily 
at baseline. After year 1, participants in arm B crossed 
over to receive CVC, while those in arms A and C 
continued with their respective treatment until the end 
of year 2 (Supporting Fig. S1). Participants were ran-
domized by permuted block randomization stratified 
by NAS at screening (4 or ≥5) and fibrosis stage (≤2 or 
>2).(15) Liver biopsies were collected at screening, year 1, 
and year 2 and were read by a central study pathologist.
StUDy oUtCoMeS
A complete listing of the prespecified study effi-
cacy endpoints has been described.(15) As the primary 
endpoint at year 1 (≥2-point improvement in NAS 
with ≥1-point improvement in either lobular inflam-
mation or hepatocellular ballooning, with no worsen-
ing of fibrosis) was not met, the results from year 2 
presented herein are exploratory analyses, which were 
not powered for statistical significance. Year 2 results 
mainly describe findings from the prespecified anal-
yses focusing on proportions of participants in the 
intent-to-treat (ITT) population with improvement 
in (1) fibrosis by ≥1 stage, (2) fibrosis by ≥1 stage and 
no worsening of steatohepatitis (i.e., the composite 
endpoint), and (3) fibrosis by ≥2 stages and no wors-
ening of steatohepatitis. Furthermore, post hoc analy-
ses were performed to evaluate the above endpoints 
in the subgroup of participants with advanced fibrosis 
(stage 2 or 3) at baseline, in addition to analyses of 
fibrosis-related biomarkers and systemic markers of 
inflammation.
StatIStICal aNalySIS
Five population data sets were defined for the 
year 2 analysis: ITT, full analysis set, modified 
ITT (mITT), per protocol, and safety analysis sets 
(Supporting Table S1). Overall, the main efficacy 
analysis at the end of year 2 was based on the ITT 
population and included evaluation of (1) effects of 
2 years of CVC treatment, comparing arm A versus 
arm C, and (2) effects of 1-year treatment with CVC, 
comparing arms A+B versus arm C (year 1 data for 
arms A and C and year 2 data for arm B) using a 
logistic regression model with factors for treatment 
group, NAS at screening (4 or ≥5), and fibrosis stage 
(≤2 or >2). In addition, to evaluate CVC response 
after 1-year treatment in crossover participants, arm 
B versus arm C were compared for the subpopula-
tion of placebo nonresponders (i.e., fibrosis stage 2 
or 3 participants who did not achieve the ≥1-stage 
fibrosis and NASH composite endpoint at year 1). 
Additional details related to methodology are 
included in the Supporting Information and have 
been described.(15,16)
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Results
patIeNt DISpoSItIoN aND 
CHaRaCteRIStICS
Participants were recruited from September 2014 
to June 2015, and the study was completed in June 
2017. Of the 812 screened, liver biopsy was con-
ducted in 610 participants and 289 were randomized 
to treatment, with biopsies available for 252 and 213 
participants at the end of year 1 and year 2, respec-
tively (Fig. 1), with fewer biopsies available in arm A 
(82%; 99/121) compared to the other groups at the 
end of year 2. Baseline characteristics of the 242 par-
ticipants who entered treatment at year 2 were gen-
erally comparable among the three groups, except for 
a higher number of patients with a history of type 2 
diabetes mellitus in arm A (Supporting Table S2). At 
baseline, 49% (119/242) of year 2 participants were 
female and mean age was 54 years. Furthermore, 39% 
(94/242) of study participants had bridging fibrosis 
(NASH CRN stage 3) and 74% (178/242) had NAS 
≥5 at screening.
eFFeCtS oF 1 yeaR oF 
tReatMeNt WItH CVC oN 
FIBRoSIS eNDpoINtS
We had previously reported that more participants 
receiving CVC (arm A) achieved ≥1-stage fibrosis 
improvement and no worsening of NASH than pla-
cebo (arm B+C) at year 1.(16) To examine the antifi-
brotic response in the totality of patients treated for 1 
year over the 2-year period, data were pooled for par-
ticipants who received CVC for 1 year and compared 
to placebo (i.e., arms A+B each after 1 year of treat-
ment versus arm C after 1  year of placebo). For this 
analysis, biopsies for arms A and C were from year 1 
and biopsies for arm B were from year 2; all were com-
pared against respective baseline biopsies. Among par-
ticipants treated with CVC for 1 year, 27.7% (57/206) 
achieved the ≥1-stage fibrosis endpoint versus 16.7% 
(12/72) of participants receiving placebo for 1 year, 
while ≥1-stage fibrosis improvement and no worsen-
ing of NASH was achieved in 19.9% (41/206) with 
CVC versus 11.1% (8/72) on placebo (OR, 2.033; 
95% CI, 0.894-4.622; P = 0.09) (Fig. 2A).

































Start of Year 2 (N=242)
(Month 13)
Treatment completers:
End of Year 2 (N=226)
(Month 24)
Early withdrawal (n=12)
•   Adverse event (n=5)
•   Withdrew consent (n=2)
•   Physician decision (n=2)
•   Lost to follow-up (n=2)
•   Other (n=1)
Liver biopsy at Year 2
•   Evaluable (n=99)
•   Non-evaluable (n=4)
•   Missing (n=42)
Early withdrawal (n=2)
•   Adverse event (n=1)
•   Withdrew consent (n=0)
•   Physician decision (n = 0)
•   Lost to follow-up (n=1)
•   Other (n=0)
Liver biopsy at Year 2
•   Evaluable (n=60)
•   Non-evaluable (n=0)
•   Missing (n=12)
Early withdrawal (n=2)
•   Adverse event (n=0)
•   Withdrew consent (n=2)
•   Physician decision (n=0)
•   Lost to follow-up (n=0)
•   Other (n=0)
Liver biopsy at Year 2
•   Evaluable (n=54
•   Non-evaluable (n=2)
•   Missing (n=16)
Excluded (n=523)
•   Not meeting eligibility criteria (n=436
•   Withdrew consent (n=31)
•   Lost to follow-up (n=12)
•   Other reasons (n=44)
Assessed for eligibility (N=812)
Underwent liver biopsy (n=610)
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Similarly, in the placebo crossover group during 
year 2 (arm B) relative to those who received pla-
cebo throughout the 2-year study (arm C) compared 
to baseline, 34.4% (21/61) and 19.7% (12/61) of 
those switching over to CVC versus 16.7% (12/72) 
and 11.1% (8/72) of those who remained on placebo 
achieved the ≥1-stage fibrosis improvement endpoint 
and the associated composite endpoint, respectively. 
Furthermore, analysis of the year 1 placebo nonre-
sponders showed that switching to CVC during the 
second year of treatment was associated with improve-
ment in fibrosis by ≥1-stage (39.0% [16/41] in arm B 
versus 28.6% [10/35] in arm C) and in the compos-
ite endpoint (24.4% [10/41] in arm B versus 17.1% 
[6/35] in arm C; OR, 1.713; 95% CI, 0.532-5.514; 
P = 0.37) (Fig. 2B).
eFFeCtS oF 2 yeaRS oF 
tReatMeNt WItH CVC oN 
FIBRoSIS eNDpoINtS
We next determined whether prolonged treat-
ment with CVC for an additional year offered further 
antifibrotic benefit beyond 1 year. Over the 2-year 
treatment period, a comparable proportion of par-
ticipants receiving CVC (arm A) or placebo (arm C) 
achieved ≥1-stage fibrosis improvement regardless of 
NASH status (22.2% [26/117] versus 19.3% [11/57]), 
while a similar proportion achieved ≥1-stage fibrosis 
improvement and no worsening of NASH (12.8% 
[15/117] in arm A versus 14.0% [8/57] in arm C) 
(Fig. 3A; ITT population). Analysis of the mITT 
population (i.e., participants in the ITT population 
with evaluable biopsies at year 2) showed that a sim-
ilar proportion of patients achieved both the ≥1-stage 
fibrosis endpoint (26.3% [26/99] versus 22.2% 
[12/54]) and the composite endpoint (15.2% [15/99] 
versus 16.7% [9/54]). To determine the impact of 
CVC treatment on those with advanced disease over 
2  years, a post hoc analysis was performed of partici-
pants with baseline NASH CRN fibrosis stage 2 or 
3 only. In this subpopulation, 10.8% (7/65) of CVC 
participants and 2.9% (1/34) of placebo participants 
achieved ≥2-stage fibrosis improvement and no wors-
ening of NASH (P  =  0.13) (Fig. 3B). Furthermore, 
when only participants with stage 3 fibrosis at baseline 
FIg. 2. Effect of 1 year of treatment with CVC on fibrosis endpoints. (A) Antifibrotic response in totality of participants treated for 
1 year (arms A+B versus arm C [year 1 data for arms A and C; year 2 data for arm B]). (B) Antifibrotic response in placebo nonresponders 
(arm B versus arm C) during year 2. Placebo nonresponders are participants with fibrosis stage 2 or 3 who did not achieve improvement 
in fibrosis by ≥1 stage and no worsening of NASH at year 1 and data analyzed from year 1 to year 2. ORs, 95% CIs, and P values are from 
ordinal logistic regression models with factors for randomized treatment group, NAS at screening (4 or ≥5), and fibrosis stage (≤2 or >2). 
Data presented for the ITT population (i.e., participants who had an evaluable year 1 biopsy and who received at least one dose of study 
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were included in this analysis, 15.8% (6/38) on CVC 
and 4.8% (1/21) on placebo achieved this endpoint 
(P = 0.18) (Fig. 3B).
DyNaMICS oF aNtIFIBRotIC 
ReSpoNSe FolloWINg 
tReatMeNt WItH CVC
To evaluate the durability of histological improve-
ment over 2 years, improvement in fibrosis by ≥1 stage 
(regardless of steatohepatitis status) was assessed in 
participants with evaluable biopsies at baseline, year 1, 
and year 2. Results from this post hoc analysis showed 
that 60.0% (18/30) of participants on CVC (arm A) 
achieved ≥1-stage fibrosis improvement at the end of 
year 1 and maintained this antifibrotic response at 
year 2 compared to the 30.0% (3/10) on placebo (arm 
C) (Fig. 4A,B), albeit the sample sizes were small. 
Importantly, 85.7% (12/14) of participants in arm 
A with stage 3 fibrosis at baseline that improved by 
≥1 stage at year 1 maintained this antifibrotic benefit 
at year 2 compared with 60.0% (3/5) of participants 
in arm C (Fig. 4A,B). Concurrent improvements in 
various parameters, including hepatocellular balloon-
ing, lobular inflammation, NAS score, and portal 
inflammation, were observed in a majority of these 
12 CVC-treated F3 participants, including 2 partic-
ipants whose fibrosis improved to stage 0 by the end 
of year 2. A comparable proportion of those on CVC 
as placebo maintained the year 1 composite fibrosis 
endpoint at the end of year 2 (28.6% [8/28] versus 
25.0% [2/8]). Among participants with fibrosis stage 
2 or 3 based on year 1 biopsy, a lower proportion of 
those in arm A experienced worsened fibrosis at the 
end of year 2 compared to arm C (13.6% [8/59] ver-
sus 17.2% [5/29]).
FIg. 3. Effect of 2 years of treatment with CVC on fibrosis endpoints (arm A versus arm C). (A) Improvement in fibrosis stage by 
≥1 stage and no worsening of steatohepatitis for the ITT and mITT populations. (B) Improvement in fibrosis stage by ≥2 stages and 
no worsening of steatohepatitis among participants with baseline NASH CRN fibrosis stage 2 or 3 (excluding stage 1) for the mITT 
population. ORs, 95% CIs, and P values are from ordinal logistic regression models with factors for randomized treatment group, NAS 
at screening (4 or ≥5), and fibrosis stage (≤2 or >2). Data presented for the ITT population (i.e., participants who had an evaluable year 
1 biopsy and who received at least one dose of study drug during year 2) and the mITT population (participants who received at least 
one dose of study drug, had an eligible screening biopsy, and had a year 2 biopsy; used for supportive analyses); participants with missing 
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eFFeCt oF CVC tReatMeNt oN 
SeVeRe FIBRoSIS
As a greater durability of antifibrotic response was 
observed in participants with severe disease, a post hoc 
analysis was performed to further evaluate the effect 
of CVC in this subpopulation (i.e., participants with 
NASH CRN stage 3 at baseline and who had eval-
uable biopsies at all time points). At year 1, 38.0% 
(18/47) and 32.0 % (15/47) of F3 CVC participants 
compared to 28.0% (14/50) and 20.0% (10/50) of F3 
placebo participants achieved the ≥1-stage fibrosis 
improvement endpoint and the composite endpoint, 
respectively (Supporting Fig. S2A). At year 2, 40.0% 
(15/38; arm A) and 50.0% (12/24; arm B) of F3 par-
ticipants receiving CVC and 29.0% (6/21; arm C) 
receiving placebo achieved ≥1-stage fibrosis improve-
ment, while 26.0% (10/38 in arm A) and 29.0% (7/24 
in arm B) on CVC and 19.0% (4/21 in arm C) on 
placebo achieved the composite endpoint (Supporting 
Fig. S2C). Additional data in F3 participants are pre-
sented in Supporting Fig. S2B,D.
eFFeCt oF plaCeBo 
tReatMeNt oN FIBRoSIS
The study requirement of three serial biopsies 
allowed us to evaluate the course of fibrosis in the pla-
cebo group throughout the 2-year treatment period. 
From baseline to end of year 1 (Fig. 5A, left panel) 
and from baseline to end of year 2 (Fig. 5A, right 
panel), 20.0% and 22.2% achieved improvement in 
fibrosis status, while 35.0% and 22.2% experienced 
deterioration in fibrosis status at the end of year 1 
and year 2, respectively. However, further analysis of 
the intermediate period from end of year 1 to end of 
year 2 showed erratic fluctuation of fibrosis stage in 
the placebo group (Fig. 5A, middle panel). The data 
show that of the 10 participants who had experienced 
1-stage improvement in fibrosis at the end of year 1, 
the majority (80.0%) worsened between year 1 and 
year 2. Conversely, of the 15 participants who expe-
rienced worsened fibrosis at the end of year 1, the 
majority (53.3%) improved between year 1 and year 2. 
Overall, this variability of fibrosis response in the 
FIg. 4. Proportion of year 1 responders maintaining antifibrotic benefit at year 2 (arm A versus arm C) for the overall population and 
stratified by fibrosis stage at baseline in the (A) placebo and (B) CVC group. Antifibrotic benefit was defined as ≥1-stage improvement in 
fibrosis from baseline. Note that there were 36 total responders in arm A at year 1; however, 6 participants had missing year 2 biopsy data 
(of whom 4 had stage 3 fibrosis at baseline) and thus were considered year 2 nonresponders and excluded from this analysis. Data presented 
are from post hoc analysis for the mITT population (participants who received at least one dose of study drug and had evaluable biopsies at 
baseline, year 1, and year 2); participants with missing postbaseline biopsies were considered nonresponders at the respective time points.
A B
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placebo group, suggestive of a “seesaw effect,” indi-
cates that the placebo participants who experienced 
improvement at year 1 were not the same participants 
who had fibrosis improvement at the end of year 2. In 
the CVC group, of the 30 participants who had expe-
rienced 1-stage improvement in fibrosis at the end of 
year 1, 40.0% maintained this status and 13.3% fur-
ther improved between year 1 and year 2, while 32.0% 
of the 25 CVC patients who experienced worsened 
fibrosis at the end of year 1 improved between year 1 
and year 2 (Fig. 5B).
CoRRelatIoN BetWeeN 
aNtIFIBRotIC ReSpoNSe aND 
FIBRoSIS-RelateD BIoMaRKeRS
Our analysis of the effect of CVC on mark-
ers of fibrosis turnover and noninvasive indices 
showed modest effects that were similar between 
the CVC and placebo groups at year 1 and year 2. 
Therefore, to determine whether there was a cor-
relation between overall changes in histology and 
biomarkers, data from all year 2 responders (i.e., all 
participants who achieved ≥1-stage fibrosis improve-
ment; total n  =  54) were pooled from all treatment 
groups and compared to year 2 nonresponders 
(those with no change or ≥1-stage fibrosis worsen-
ing; total n  =  163) and evaluated from baseline to 
year 2. From a mean baseline of 14.3 ng/mL in both 
groups, reductions in levels of N-terminal type 3 
collagen propeptide (PRO-C3) were observed in the 
responder group over the 2-year treatment period, 
while PRO-C3 levels remained near baseline levels 
in the nonresponder group over 2  years (Fig. 6A). 
Notably, baseline PRO-C3 levels were higher with 
advanced fibrosis (F1, 12.0 ng/mL; F2, 13.0 ng/mL; 
F3, 16.5  ng/mL). Correlation between histologi-
cal response and fibrosis indices showed that over 
FIg. 5. Dynamics of antifibrotic response within the placebo (arm C) group and the CVC (arm A) group. Change in fibrosis by 1 stage 
from baseline to end of year 1 (left panels) and end of year 2 (right panels) in (A) the placebo (arm C) group and (B) the CVC (arm A) 
group. Fibrosis response from year 1 to year 2 in participants whose fibrosis had either improved, had no change, or worsened at end of year 
1 (middle panels). Data presented for the mITT population (participants who received at least one dose of study drug and had evaluable 
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2 years aspartate aminotransferase (AST)-to-platelet 
ratio index (APRI) and Fibrosis-4 (FIB-4) score 
levels remained near baseline levels for responders, 
while reductions in enhanced liver fibrosis (ELF) 
score were observed over 18 months before returning 
to baseline levels at year 2 (Fig. 6B-D). Conversely, 
from their respective baseline levels, increases in 
APRI and FIB-4 scores were observed over 2 years 
in nonresponders, while ELF score levels remained 
close to baseline levels.
Additional biomarker analyses were performed to 
further understand the clinical characteristics associ-
ated with fibrosis progression among placebo-treated 
participants (arm B+C, n = 126). Fibrosis progressors 
were defined as participants with ≥1-stage fibrosis 
worsening (n  =  37 [arm B+C] at year 1 and n  =  21 
[arm C] at year 2), and nonprogressors were defined 
as those with no change or ≥1-stage fibrosis improve-
ment (n = 89 [arm B+C] at year 1 and n = 16 [arm C] 
at year 2). At baseline, notably higher levels of trans-
aminases were observed among progressors compared 
to nonprogressors (alanine aminotransferase [ALT], 
78.0 versus 60.0 IU/L; AST, 58.4 versus 44.4 IU/L), 
NAS ≥5 (89.2% versus 70.8%), hepatocellular bal-
looning grade 2 (64.9% versus 50.6%), and stage 1 
fibrosis (64.9% versus 20.2%), albeit there was a lower 
proportion of participants with stage 3 fibrosis (10.8% 
versus 51.7%). No differences were observed between 
the two groups in age, body mass index, diabetes sta-
tus, or stage 2 fibrosis at baseline.
FIg. 6. Correlation between histological response and biomarkers. Mean changes (±SEM) in (A) PRO-C3, (B) APRI, (C) FIB-4, and 
(D) ELF scores from baseline to year 2 in responders and nonresponders. Histological data were stratified by year 2 responders (defined 
as participants who achieved ≥1-stage fibrosis improvement; total n = 54) or nonresponders (participants who experienced no change 
in fibrosis or those with ≥1-stage worsening in fibrosis; total n = 163). Data from all treatment arms (arm A [CVC] + arm B [placebo/
CVC] + arm C [placebo]) were pooled in this analysis and evaluated over the 2-year treatment period. Analysis based on participants with 
evaluable biopsies (n = 54 for responders and n = 163 for nonresponders) and data presented at each time point for those with available 
samples for biomarker analyses. APRI was calculated using the following formula: (AST level [U/L]/platelet count [109/L]) × 100. FIB-4 
was calculated using the following formula: (Age [years] × AST [U/L])/(platelet count [109/L] × (ALT [U/L])1/2). ELF data were calculated 
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eFFeCt oF CVC oN MaRKeRS oF 
SySteMIC INFlaMMatIoN
In line with its function as a CCR2 and CCR5 
inhibitor, increases in levels of the ligands CCL2 and 
CCL4 were seen in participants treated with CVC 
over the entire 2-year period (arm A) and in those who 
crossed over to CVC in the second year of treatment 
(arm B) (Supporting Table S3). Moreover, treatment 
with CVC was associated with reductions in circulat-
ing markers of systemic inflammation, such as IL-6, 
and in markers associated with cardiovascular out-
comes, including high-sensitivity CRP and fibrinogen. 
From baseline, reductions in mean levels of fibrinogen 
were observed within the initial month of treatment in 
the CVC group (arm A), which were sustained until 
the end of the 2-year treatment period (Supporting 
Figs. S3). In comparison, no changes in fibrinogen 
levels were observed in the placebo groups (arms 
B and C) over the first year of treatment; however, 
upon crossing over to CVC treatment at the start of 
year 2, rapid reductions in fibrinogen were observed in 
arm B, which were sustained throughout the second 
year of treatment, while levels remained near base-
line for arm C. No clinically meaningful differences 
were noted between the CVC and placebo treatment 
groups in levels of liver transaminases, fasting meta-
bolic parameters, body weight or related parameters, 
or NAFLD activity score (Supporting Tables S4-S6).
SaFety aND toleRaBIlIty
The overall incidence of treatment-emergent 
adverse events (TEAEs) was similar in the CVC and 
placebo groups, the majority of which were mild to 
moderate in severity (Supporting Table S7). Treatment 
discontinuations due to TEAEs were only reported in 
arm A (4.1% [5/121]). Overall, a higher rate of seri-
ous adverse events (SAEs) was reported in arm C, 
with only one SAE resulting in premature discontin-
uation (arm A), no SAEs being assessed as related to 
treatment, and no deaths being reported throughout 
the 2-year study.
TEAEs related to infections were the most fre-
quently reported events in year 2, with a higher inci-
dence reported in arm A (Supporting Table S8), none 
of which were related to the respective treatments 
or resulted in drug withdrawal. Nasopharyngitis was 
reported at a higher rate in the CVC groups at year 2 
(9.1% in arm A and 8.2% in arm B) compared to pla-
cebo (3.3%), while comparable rates of upper respira-
tory tract infection were reported in arm A and arm 
C (6.6% versus 5.0%), with a higher rate in arm B 
(8.2%) at year 2 (Supporting Table S8). Of the gas-
trointestinal events, nausea was reported more fre-
quently in arm A compared to arm C (5.8% versus 
3.3%), while diarrhea was more frequent in arm C 
(1.7% versus 8.3%). The incidence of grade 3 or 4 
laboratory abnormalities was generally similar among 
the treatment groups (Supporting Table S9). Overall, 
the proportion of participants with elevations in 
liver biochemistry requiring further evaluation was 
10.4% (15/144) in the CVC group (arm A) and 7.6% 
(11/144) in the placebo groups (arms B+C) during 
the first year of treatment. Of note, among those with 
elevations in liver biochemistry during year 1, two 
grade 3 hepatobiliary adverse events of “autoimmune 
hepatitis” were reported (one participant each in arm 
A and arm C), and one participant had a postbase-
line liver biopsy suggestive of autoimmune hepatitis 
in arm A, none of whom continued treatment in year 
2. During year 2, 3.3% (4/121) of participants in arm 
A, 3.3% (2/61) in arm B, and 3.3% (2/60) in arm C 
had elevations in liver biochemistry requiring further 
evaluation. Overall, exposure to study medication was 
comparable across all treatment groups throughout 
the study (Supporting Table S10). Moreover, ~85% of 
patients experienced a change in dosage or concomi-
tant medications during year 2, with comparable pro-
portions between arms A and C (86.0% and 91.7%, 
respectively) and 77.0% in arm B.
Discussion
Herein, we present data from the year 2 exploratory 
analyses, which indicate that treatment with CVC for 
2 years was not associated with further improvement 
in fibrosis beyond the effect observed after 1 year 
compared to placebo. Nonetheless, the year 2 data 
suggest that even if no or limited additional fibrosis 
improvement is observed, the durability of the fibro-
sis benefit (those who maintained a lower fibrosis 
stage than at baseline, as measured 1 year later) was 
higher with CVC than with placebo, thus suggest-
ing qualitative differences between pharmacologically 
induced fibrosis regression and fibrosis reversal owing 
to natural fluctuations of the disease. Moreover, the 
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durability of antifibrotic response obtained on CVC 
treatment was higher in those with advanced disease 
and highest in those with stage 3 fibrosis. These year 2 
findings also corroborate the antifibrotic activity 
of CVC as was observed in year 1, as evidenced by 
a greater antifibrotic response in the totality of par-
ticipants treated with CVC for 1 year compared to 
placebo (i.e., arm A+B pooled analysis versus arm C). 
Furthermore, among the year 1 placebo nonrespond-
ers, 39% and 24% of those who crossed over to CVC 
achieved ≥1-stage fibrosis improvement and ≥1-stage 
fibrosis improvement and no worsening of NASH, 
respectively, compared to 29% and 17% of those 
who remained on placebo at year 2. Over 2 years of 
treatment, a similar proportion on CVC or placebo 
achieved the ≥1-stage fibrosis and NASH compos-
ite endpoint; however, a greater proportion on CVC 
achieved the ≥2-stage fibrosis and NASH composite 
endpoint (10.8% versus 2.9%), albeit the sample sizes 
were small. Interestingly, for a ≥2-stage fibrosis reduc-
tion, the difference from placebo was of the same 
order of magnitude after 1 and 2 years of therapy, 
thus suggesting that patients with a strong antifibrotic 
response to CVC maintained longer-term benefit.
Because liver fibrosis is independently associated 
with long-term clinical outcomes and fibrosis severity 
is associated with increasing hazard ratios for hepatic 
mortality, the histological benefit of CVC demon-
strated here might translate into long-term clinical 
benefit should longer and larger studies confirm these 
present findings.
This study design required collection of serial 
biopsies over 2  years, which allowed us to further 
investigate two major clinical aspects of NASH and 
liver fibrosis: the durability of antifibrotic response 
in CVC-treated patients and the course of disease 
fluctuation in placebo-treated patients. To the first 
point, among those who had evaluable biopsies at 
all time points, 60% on CVC and 30% on placebo 
who achieved ≥1-stage fibrosis improvement at year 1 
maintained this antifibrotic benefit at year 2. This 
durability in response was driven mostly by partici-
pants who had stage 3 fibrosis at baseline, indicating 
that CVC may exert a pronounced antifibrotic effect 
in those with advanced disease, where CCR2/CCR5 
signaling may play a greater role in the pathophysiol-
ogy of fibrosis.(17) To the second point, a pronounced 
“seesaw effect” in fibrosis response was evident in the 
placebo group, wherein the majority (80%) of those 
whose fibrosis had improved by 1 stage at the end of 
year 1 actually worsened in the period from the end 
of year 1 to end of year 2, while conversely, a major-
ity (53%) of those whose fibrosis had worsened at the 
end of year 1 actually improved by 1 stage at the end 
of year 2. Elevated liver transaminase levels at base-
line were found to be associated with progression of 
fibrosis in the placebo groups. Fluctuations in fibrosis 
among participants in the placebo group may be due 
to the high variability in the natural course of fibro-
sis, particularly in patients with less severe disease, 
and corroborate reports from previous NASH studies 
that documented substantial changes in the placebo 
arms.(18-20) It also emphasizes the need for future 
antifibrotic trials to have large sample sizes as a small 
sample size in the placebo arm might lead to larger 
fluctuations of the response rate. Analysis of the effect 
of CVC on fibrosis-related biomarkers was also lim-
ited by the small sample size. However, pooling of the 
treatment groups allowed us to evaluate the correla-
tion between changes in histology and fibrosis-related 
biomarkers. Of the evaluated biomarkers, we observed 
a consistent reduction in levels of PRO-C3, a pro-
peptide that reflects formation of type III collagen, 
among participants with fibrosis improvement.(21) The 
baseline PRO-C3 levels in this study of 16.5 ng/mL 
within the F3 population were in line with the 
recently reported cutoff of 15.6 ng/mL for advanced 
fibrosis (≥F3); therefore, these exploratory analyses 
suggest that PRO-C3 may have prognostic value as a 
biomarker in NASH.(22)
The overall safety profile of CVC was comparable 
to placebo and well tolerated over the 2 years. The 
types, severity, and frequency of TEAEs reported after 
2 years of CVC treatment were consistent with those 
reported after 1 year of treatment, with no new safety 
findings identified in year 2. Overall, a comparable pro-
portion of participants in all groups reported TEAEs, 
the majority of which were mild to moderate in sever-
ity; and no deaths occurred during the study. Few 
TEAEs resulted in study discontinuations during year 
2 (all in arm A), and a similar proportion in all groups 
(3.3%) had elevations in liver biochemistry requiring 
further evaluation. Diarrhea, nausea, abdominal pain, 
and arthralgia were experienced more frequently in 
the CVC groups than the placebo group, which was 
consistent with prior CVC studies.(13,14,23)
Treatment with CVC was associated with reduc-
tions in markers of systemic inflammation, providing 
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further evidence of its anti-inflammatory activity in 
response to sustained target engagement. Although 
the study was not designed or powered to demonstrate 
cardiovascular benefit of treatment, this property of 
CVC is potentially relevant as systemic inflammation 
is an important driver of adverse cardiovascular out-
comes. The latter are still the most frequent cause of 
death in patients with NASH, and data support an 
independent contribution of NASH to cardiovascu-
lar disease development.(24) In the placebo-to-CVC 
crossover group, rapid reductions in fibrinogen were 
observed soon after switching to CVC, which were 
sustained until the end of treatment, accompa-
nied by concurrent increases in CCL2 and CCL4. 
Nonetheless, there were some variations in the extent 
of reduction in biomarkers of systemic inflammation, 
which might be attributed to redundancy and com-
pensatory mechanisms in chemokine signaling.(17,25) 
However, no differences in changes in body weight 
or related parameters, insulin sensitivity, or fasting 
metabolic parameters were observed with CVC com-
pared to placebo, suggesting that CVC likely does 
not worsen underlying metabolic disease or may be 
metabolically neutral. Consequently, treatment reg-
imens that combine agents with anti-inflammatory 
and antifibrotic activities (such as CVC) with other 
agents that target metabolic components may repre-
sent a new paradigm in the treatment of NASH.(7)
In both year 1 and year 2 analyses, CVC showed a 
beneficial impact on fibrosis without affecting the his-
tological features of steatohepatitis. This lack of effect 
on steatohepatitis may be attributed to compensatory 
mechanisms driven by chemokine interactions with 
other cognate receptors than those blocked by CVC 
or other pathological drivers such as hepatocyte oxi-
dative stress, endoplasmic reticulum stress, and apop-
tosis that are not directly modulated by CVC.(25) It 
may also be that crude histological changes measured 
by current histological classifications (lobular inflam-
mation of unspecified cellular origin and hepatocyte 
ballooning) do not capture subtle immune cell mod-
ifications induced by chemokine receptor blockade. 
This, together with the lack of effect of CVC on insu-
lin resistance or associated metabolic changes opens 
the possibility of further benefit from combination 
therapies with other agents that target liver metab-
olism and steatohepatitis such as farnesoid X recep-
tor (FXR) agonists, peroxisome proliferator–activator 
receptor agonists, or fibroblast growth factor-21.(7,25) 
One such combination treatment with tropifexor (an 
FXR agonist) and CVC is currently under way in a 
phase 2 study of adult patients with NASH and liver 
fibrosis (TANDEM study, NCT03517540).
The key limitation of our study was a higher 
attrition rate than was anticipated over the 2 years 
of treatment (23% versus 15%), which might be 
associated with the protocol requirement of three 
serial biopsies over a 2-year period. While currently 
the gold standard in assessing clinical benefit and 
disease severity, liver biopsies are otherwise pain-
ful and invasive and may be associated with com-
plications.(26,27) Moreover, the missing liver biopsy 
data predominantly affected the CVC group (arm 
A), which limited the evaluation of the year 2 data, 
particularly among the year 1 responders without 
evaluable biopsies at year 2, who thus were consid-
ered nonresponders at year 2. This is an important 
reminder of the need to identify diagnostic and 
prognostic biomarkers independent of histological 
sampling. Another limitation of the study was the 
limited sample size of patients with severe disease; 
nonetheless, our post hoc analysis on ≥2-stage fibrosis 
improvement without impact on underlying steato-
hepatitis suggests that patients with stage 3 fibrosis 
may potentially be the ideal target population for 
CVC. Based on these limitations and our overall 
observations from the phase 2b CENTAUR study, the 
ongoing AURORA phase 3 study (NCT03028740) 
was designed to evaluate and confirm the efficacy 
and safety of CVC for the treatment of liver fibrosis 
in adults with NASH. The AURORA study differs 
from CENTAUR in two main aspects: (1) the phase 
3 study population specifically includes patients 
who are likely to benefit from treatment with CVC 
(i.e., those with stage 2 or 3 fibrosis) and excludes 
patients with stage 1 fibrosis who comprised 34% 
of the CENTAUR population and (2) the primary 
outcomes focus on improvement of liver fibrosis 
(i.e., improvement in fibrosis by ≥1 stage and no 
worsening of steatohepatitis). Nevertheless, data 
from CENTAUR support the timing of liver biopsy 
for the AURORA study, which will be collected at 
baseline, year 1 (primary endpoint analysis), and year 
5 (end of study). Notably, previous phase 2 trials 
were designed for a single, short-term evaluation of 
histological endpoints. In contrast, CENTAUR is a 
unique attempt to assess the durability of the antifi-
brotic response beyond the initial, 1-year evaluation 
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together with the variability of the placebo response 
in the long term. In current phase 3 trials, follow-up 
data beyond the interim analysis will only be avail-
able several years from now.
In conclusion, treatment with CVC resulted in an 
early antifibrotic benefit, which was maintained par-
ticularly in the subset of patients with advanced fibro-
sis. The drug was well tolerated, with a similar safety 
profile as placebo. The present results provide addi-
tional evidence of the potential of CVC as a safe and 
efficacious pharmacologic treatment for liver fibrosis 
in adults with NASH, requiring validation in a larger 
phase 3 trial. These results also identify CVC as a 
relevant partner for future combinations with agents 
that target the metabolic components of NASH, 
an important consideration given the multifactorial 
pathogenesis of this disease.
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